Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Artelo Biosciences Inc (ARTL)

Artelo Biosciences Inc (ARTL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,175
  • Shares Outstanding, K 4,140
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,170 K
  • 60-Month Beta 2.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0800 +15.73%
on 07/16/20
1.3500 -7.41%
on 07/16/20
-0.0001 (-0.01%)
since 07/07/20
3-Month
1.0300 +21.35%
on 05/14/20
1.7500 -28.58%
on 06/02/20
-0.1201 (-8.77%)
since 05/07/20
52-Week
0.6100 +104.90%
on 03/20/20
4.4200 -71.72%
on 02/03/20
-1.7251 (-57.99%)
since 08/07/19

Most Recent Stories

More News
LD Micro Announces Preliminary List of Presenters for the LD 500

LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACER : 5.41 (+21.03%)
ACU : 22.49 (+2.23%)
AEY : 2.37 (+2.60%)
ADIL : 1.8600 (-3.12%)
ADXS : 0.5500 (-3.44%)
AEHR : 2.12 (-6.05%)
AIM : 2.99 (+2.40%)
AIRI : 1.2700 (-4.51%)
KERN : 6.55 (-1.65%)
ALIM : 6.31 (-8.28%)
ALLT : 11.55 (+0.70%)
AMS : 2.16 (+0.93%)
ANVS : 5.55 (-2.12%)
APEN : 1.5000 (-7.41%)
APM : 3.54 (-0.28%)
AQB : 2.51 (-17.97%)
ARTL : 1.2499 (-0.01%)
ARHH : 0.7000 (-7.89%)
ATOM : 11.84 (-5.28%)
ATOS : 3.83 (-0.78%)
ACU.VN : 0.115 (unch)
AUTO : 1.7500 (-1.69%)
AYRO : 4.17 (-2.80%)
AYTU : 1.3800 (-0.72%)
AZRX : 1.1700 (+7.34%)
BLDP : 14.74 (-1.11%)
BELFA : 12.88 (+2.98%)
BCDA : 2.67 (-1.84%)
BIOC : 1.0100 (-11.40%)
BMRA : 8.81 (-0.68%)
BSGM : 7.43 (-2.49%)
BLNK : 11.85 (-2.67%)
BKEP : 1.4300 (unch)
CLBS : 2.44 (+4.72%)
CLXT : 5.59 (+7.50%)
ASUR : 7.31 (-0.27%)
BLGO : 0.1750 (-1.41%)
Artelo Biosciences Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Business Update

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system and related biological signaling...

ARTL : 1.2499 (-0.01%)
Artelo Biosciences to Participate in BIO Digital and The Investor Summit Conferences

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system and related pathways, announced today that it will be...

ARTL : 1.2499 (-0.01%)
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

The Virtual Summer Summit will take place on June 9-12, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below...

ACCO : 7.01 (-0.43%)
ALIM : 6.31 (-8.28%)
ANVS : 5.55 (-2.12%)
AQB : 2.51 (-17.97%)
ARTL : 1.2499 (-0.01%)
AVLNF : 0.0640 (+9.40%)
BLCM : 7.06 (-5.74%)
NDRA : 0.9735 (-1.07%)
EFOI : 6.60 (+8.91%)
EQ : 9.48 (-2.77%)
EXROF : 0.6930 (+0.93%)
HL : 6.12 (-7.97%)
HSII : 21.24 (+5.10%)
HSDT : 0.5351 (-6.12%)
HGBL : 2.7700 (unch)
IPWR : 7.01 (-2.50%)
LINC : 5.23 (-7.10%)
MBII : 1.3400 (+13.56%)
MLSS : 1.8800 (-2.08%)
MYSZ : 1.2900 (+1.57%)
NBEV : 2.42 (+5.68%)
ONCS : 4.01 (-4.52%)
OGEN : 1.0600 (-0.93%)
SFE : 6.27 (+4.50%)
SLS : 3.42 (-2.56%)
PIXY : 4.77 (-0.63%)
SGLB : 2.74 (-2.14%)
SOTK : 3.1000 (+3.68%)
TNXP : 1.1600 (-3.33%)
TGA : 0.6000 (-0.84%)
URG : 0.5400 (-2.37%)
Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing proprietary therapeutics that target the endocannabinoid system and related biological signaling...

ARTL : 1.2499 (-0.01%)
Artelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system and related biological signaling...

ARTL : 1.2499 (-0.01%)
Artelo Biosciences to Present at the Spring Investor Summit on March 25th

LA JOLLA, CA / ACCESSWIRE / March 23, 2020 / (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that it will be...

ARTL : 1.2499 (-0.01%)
Artelo Biosciences to Present at Biocom's 10th Annual Global Life Sciences Partnering Conference

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that Gregory D. Gorgas, President and...

ARTL : 1.2499 (-0.01%)
Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program

FABP5 platform under exclusive license to Artelo Biosciences

ARTL : 1.2499 (-0.01%)
Artelo Biosciences to Present at the LSX World Congress in London

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the LSX...

ARTL : 1.2499 (-0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ARTL with:

Business Summary

Artelo Biosciences Inc. is a biopharmaceutical company. It is engaged in development and commercialization of proprietary therapeutics targeting the endocannabinoid system. The company's product pipeline consists of ART27.13, ART12.11 and ART26.12 which are in clinical stage. Artelo Biosciences Inc....

See More

Key Turning Points

2nd Resistance Point 1.4300
1st Resistance Point 1.3399
Last Price 1.2499
1st Support Level 1.1499
2nd Support Level 1.0500

See More

52-Week High 4.4200
Fibonacci 61.8% 2.9646
Fibonacci 50% 2.5150
Fibonacci 38.2% 2.0654
Last Price 1.2499
52-Week Low 0.6100

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar